Citigroup
LOGC

Citigroup’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Citigroup’s Portfolio LOGC Stock Details LOGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,888
Closed -$1K – 6611
2022
Q2 		$1K Buy
+1,888
New +$955 ﹤0.01% 6167
2021
Q3 		– Sell
-300
Closed -$1K – 6477
2021
Q2 		$1K Sell
300
-1,086
-78% -$5.53K ﹤0.01% 6078
2021
Q1 		$10K Sell
1,386
-1,953
-58% -$16.1K ﹤0.01% 5666
2020
Q4 		$25K Buy
3,339
+2,454
+277% +$16.4K ﹤0.01% 6513
2020
Q3 		$8K Sell
885
-930
-51% -$7.06K ﹤0.01% 6793
2020
Q2 		$15K Sell
1,815
-330
-15% -$2.17K ﹤0.01% 6840
2020
Q1 		$11K Buy
2,145
+457
+27% +$3.55K ﹤0.01% 7021
2019
Q4 		$12K Buy
1,688
+532
+46% +$4.81K ﹤0.01% 7156
2019
Q3 		$12K Sell
1,156
-1,178
-50% -$12.6K ﹤0.01% 7004
2019
Q2 		$31K Buy
2,334
+245
+12% +$3.25K ﹤0.01% 6854
2019
Q1 		$21K Buy
2,089
+1,600
+327% +$14.9K ﹤0.01% 6941
2018
Q4 		$5K Buy
+489
New +$5.91K ﹤0.01% 7370

Other funds holding LOGC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Citigroup's LOGC Position: Q3 2022 in Review

Citigroup sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q3 2022, closing a stake of 1,888 shares — an estimated $1K sold.

Citigroup first reported a position in LOGC in Q4 2018 and held it in 12 quarters. The position peaked at $31K in Q2 2019. 39 funds tracked by Wall St. Rank hold LOGC as of Q3 2022.

  • Citigroup reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Citigroup sold 1,888 LogicBio Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $1K.
  • Citigroup first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q4 2018 and held it in 12 quarters.
  • Citigroup's LogicBio Therapeutics, Inc. Common Stock position peaked at $31K in Q2 2019.
  • 39 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Citigroup's 13F filing for Q3 2022, filed 10 Nov 2022.